Investor Relations

Press Releases

Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria

Read More

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2

Read More

Advaxis to Host Analyst & Investor Day on February 3, 2015

Read More

Advaxis to Present at the Noble Financial Capital Markets 11th Annual Investor Conference

Read More

Advaxis Provides 2014 Year-End Review and 2015 Outlook

Read More

Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer

Read More

Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2

Read More

Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall

Read More

Advaxis Completes $17 Million Financing

Read More

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers

Read More